Effects of AGOMELATINE (cas 138112-76-2) on electrocorticogram activity on penicillin-induced seizure model of rats
-
Add time:08/18/2019 Source:sciencedirect.com
AGOMELATINE (cas 138112-76-2) is a new antidepressant drug acting as an antagonist of 5-hydroxytryptamine receptor 2C (5-HTR2C) and agonist of melatonergic receptors 1 and 2 (MT1 and MT2). Because of this dual action, it is an atypical antidepressant. The aim of this study was to investigate chronic anticonvulsant effects of agomelatine on penicillin-induced epilepsy model. Adult male Sprague–Dawley rats divided into four groups and were administered with tap water (vehicle), and agomelatine doses of 10 mg/kg, 50 mg/kg and 100 mg/kg for 14 days via oral gavage. After the last doses were given, epileptic seizures were induced by intracortical penicillin (500 IU/2.5 μl) application in rats under urethane (1.25 g/kg intraperitoneal) anesthesia. Electrocorticogram (ECoG) recordings were obtained from the somatomotor cortex through 90 min, and spike frequencies and amplitudes were analyzed. The spike frequency analyses revealed that only 50 mg/kg agomelatine administration decreased the spike frequencies of hypersynchronous discharge of neurons caused by penicillin (p < 0.05). No significant differences in amplitudes between experimental groups were observed. In addition, mRNA expressions of vesicular glutamate transporter 1 (VGLUT1) and vesicular gamma-aminobutyric acid transporter (VGAT) in response to the agomelatine active dose, 50 mg/kg, showed no significant effect of agomelatine on the mRNA expression. Our results indicate that chronic treatment with agomelatine may have potential anticonvulsant effects. Agomelatine may be a promising drug for epilepsy patients having depression due to its antiepileptic and antidepressant effects.
We also recommend Trading Suppliers and Manufacturers of AGOMELATINE (cas 138112-76-2). Pls Click Website Link as below: cas 138112-76-2 suppliers
Prev:Selective crystallization of AGOMELATINE (cas 138112-76-2) from molten state induced by polymer
Next:Oxymatrine ameliorates AGOMELATINE (cas 138112-76-2)-induced hepatocyte injury through promoting proteasome-mediated CHOP degradation) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- AGOMELATINE (cas 138112-76-2) treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light08/25/2019
- Mucoadhesive olaminosomes: A novel prolonged release nanocarrier of AGOMELATINE (cas 138112-76-2) for the treatment of ocular hypertension08/24/2019
- Behavioural pharmacologyStudies on the reproductive effects of chronic treatment with AGOMELATINE (cas 138112-76-2) in the rat08/23/2019
- Research paperEffect of AGOMELATINE (cas 138112-76-2) 25–50 mg on functional outcomes in patients with major depressive disorder08/22/2019
- Spike–Wave Discharges and Sleep–Wake States during Circadian Desynchronization: No Effects of AGOMELATINE (cas 138112-76-2) upon Re-Entrainment08/21/2019
- AGOMELATINE (cas 138112-76-2)-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus08/20/2019
- Oxymatrine ameliorates AGOMELATINE (cas 138112-76-2)-induced hepatocyte injury through promoting proteasome-mediated CHOP degradation08/19/2019
- Selective crystallization of AGOMELATINE (cas 138112-76-2) from molten state induced by polymer08/17/2019
- Research articleEffects of AGOMELATINE (cas 138112-76-2) in rotenone-induced Parkinson’s disease in rats08/16/2019